Following a pivotal Phase I/II success demonstrating substantial slowing of Huntington’s disease, UniQure plans regulatory submission in early 2026, potentially marking the first approved gene therapy for this neurodegenerative condition. The results have fueled a strong market response, reflecting confidence in a novel therapeutic that offers a significant shift from symptomatic treatments to disease modification. This milestone exemplifies progress in applying gene therapy to complex CNS disorders.